|
WU-MDACC Inter-Institutional Molecular Imaging Center
|
5P50CA094056-15
|
$1,428,925
|
$85,736
|
ACHILEFU, SAMUEL
|
WASHINGTON UNIVERSITY
|
|
Vaccine Immunotoxin and Radioimmunotherapy of Primary and Metastatic CNS Tumors
|
5P01CA154291-04
|
$3,698,322
|
$776,648
|
BIGNER, DARELL
|
DUKE UNIVERSITY
|
|
Uncover the mechanisms regulating the biogenesis and decay of miRNAs in cancer
|
ZIA BC 011566
|
$925,596
|
$277,679
|
Gu, Shuo
|
CCR (NCI)
|
|
UCLA Tumor Immunology Training Program
|
3T32CA009120-39S1
|
$39,503
|
$7,901
|
TEITELL, MICHAEL
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
|
UCLA Tumor Immunology Training Program
|
5T32CA009120-39
|
$441,837
|
$88,367
|
TEITELL, MICHAEL
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
|
Translational Research in Breast Cancer (SPORE)
|
5P50CA186784-02
|
$2,184,998
|
$131,100
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
TRAINING IN CANCER BIOLOGY AND TRANSPLANTATION
|
2T32CA009515-31
|
$563,174
|
$563,174
|
PRESS, OLIVER
|
UNIVERSITY OF WASHINGTON
|
|
Tissue-specific tumor suppressor effects of p53
|
1R01CA200256-01
|
$400,089
|
$200,045
|
MANFREDI, JAMES
|
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
|
|
Therapeutic Targeting of Malignant Glioma Stem Cells
|
1R35CA197725-01
|
$709,490
|
$354,745
|
LESNIAK, MACIEJ
|
UNIVERSITY OF CHICAGO
|
|
The University of Texas M. D. Anderson Cancer Center SPORE in Ovarian Cancer
|
3P50CA083639-15S1
|
$901,656
|
$108,199
|
BAST, ROBERT
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
|
The GNAQ pathway as a therapeutic target in uveal melanoma
|
5R01CA142873-06
|
$310,970
|
$102,620
|
BASTIAN, BORIS
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
The control of the breast cancer stem cell state by snail-driven EMT program
|
1K99CA194160-01
|
$116,651
|
$38,495
|
YE, XIN
|
WHITEHEAD INSTITUTE FOR BIOMEDICAL RES
|
|
The Antigen Targeting Core
|
ZIC BC 011030
|
$200,110
|
$100,055
|
Parkhurst, Maria
|
CCR (NCI)
|
|
TGFbeta Blockade in MART TCR-Engineered T Cell Melanoma Immunotherapy in Man
|
5R01CA164333-03
|
$352,335
|
$176,168
|
KOYA, RICHARD
|
ROSWELL PARK CANCER INSTITUTE CORP
|
|
Telomere Biology
|
ZIA BC 011519
|
$1,108,669
|
$22,173
|
Cooper, Julia
|
CCR (NCI)
|
|
TCR Gene Transfer for Treating HCV-Associated Malignancies
|
5F30CA180731-02
|
$29,942
|
$29,942
|
SPEAR, TIMOTHY
|
LOYOLA UNIVERSITY CHICAGO
|
|
TCR Gene Modified T Cells for Adoptive Immunotherapy
|
5P01CA154778-05
|
$3,406,082
|
$1,873,345
|
NISHIMURA, MICHAEL
|
LOYOLA UNIVERSITY CHICAGO
|
|
Targeting Translation Control in Malignant Glioma
|
5R01CA124756-09
|
$253,655
|
$253,655
|
GROMEIER, MATTHIAS
|
DUKE UNIVERSITY
|
|
Targeting orphan nuclear receptor TR3/Nur77 for tumor angiogenesis
|
1R03CA191463-01A1
|
$87,000
|
$43,500
|
ZENG, HUIYAN
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Targeting Oncogene Expression to Skin in Transgenic Mice
|
5R01CA052607-23
|
$475,014
|
$475,014
|
ROOP, DENNIS
|
UNIVERSITY OF COLORADO DENVER
|
|
Targeting epigenetic regulators using bacterial macromolecule delivery
|
5R01CA188382-02
|
$311,561
|
$311,561
|
FORBES, NEIL
|
UNIVERSITY OF MASSACHUSETTS AMHERST
|
|
Targeting CXCR4 and microRNA as Therapy for Chondrosarcoma
|
5R01CA166089-03
|
$280,000
|
$280,000
|
TEREK, RICHARD
|
RHODE ISLAND HOSPITAL
|
|
Targeting Cancer miRNAs by Adoptive Transfer of Programmed B Lymphocytes
|
5R21CA178674-02
|
$168,563
|
$84,282
|
ZANETTI, MAURIZIO
|
UNIVERSITY OF CALIFORNIA SAN DIEGO
|
|
Targeted-and Image-Based Adenovirus Cancer Therapeutic Vectors
|
5R01CA154697-05
|
$469,520
|
$469,520
|
CURIEL, DAVID
|
WASHINGTON UNIVERSITY
|
|
Targeted therapy of B cell malignances with CAR-T cells of defined composition
|
5R01CA136551-07
|
$560,424
|
$280,212
|
RIDDELL, STANLEY
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
Targeted Platinates/siRNA Combination Therapy for Resistant Lung Cancer
|
5R21CA179652-02
|
$202,928
|
$50,732
|
AMIJI, MANSOOR
|
NORTHEASTERN UNIVERSITY
|
|
Targeted Improvement in Stem Cell Therapy for Leukemia and Bone Marrow Failure Sy
|
5R01CA157537-05
|
$317,475
|
$317,475
|
PANG, QISHEN
|
CINCINNATI CHILDRENS HOSP MED CTR
|
|
T-T interactions between naive and memory CD8+ T cells
|
ZIA BC 011586
|
$45,547
|
$45,547
|
Klebanoff, Christopher
|
CCR (NCI)
|
|
T-cell receptor gene therapy for human papillomavirus-positive cancers
|
ZIA BC 011479
|
$476,976
|
$357,732
|
Hinrichs, Christian
|
CCR (NCI)
|
|
Synergistic chemo-siRNA combination therapy
|
5R01CA158300-05
|
$372,483
|
$372,483
|
WIENTJES, M
|
OPTIMUM THERAPEUTICS, LLC
|
|
Survivin-targeting miRNAs in erbB3 promotion of erbB2-positive breast cancer
|
5R03CA181918-02
|
$77,646
|
$38,823
|
LIU, BOLIN
|
UNIVERSITY OF COLORADO DENVER
|
|
Stem Cell Gene Therapy Following R-EPOCH for Non-Hodgkin Lymphoma in AIDS Patient
|
5U01CA183012-02
|
$496,292
|
$248,146
|
ZAIA, JOHN
|
CITY OF HOPE/BECKMAN RESEARCH INSTITUTE
|
|
SPORE: Developing New Rationale, Personalized Medicine for Lung Cancer
|
5P50CA070907-17
|
$2,041,142
|
$408,228
|
MINNA, JOHN
|
UT SOUTHWESTERN MEDICAL CENTER
|
|
SPORE: Brain Tumore SPORE Grant
|
5P50CA097257-13
|
$2,185,000
|
$109,250
|
BERGER, MITCHEL
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
SPORE in Skin Cancer
|
5P50CA174523-02
|
$2,185,000
|
$87,400
|
HERLYN, MEENHARD
|
WISTAR INSTITUTE
|
|
SPORE in Prostate Cancer
|
5P50CA058236-20
|
$1,793,395
|
$358,679
|
NELSON, WILLIAM
|
JOHNS HOPKINS UNIVERSITY
|
|
SPORE In Prostate Cancer
|
5P50CA092629-15
|
$1,901,412
|
$209,155
|
SCHER, HOWARD
|
SLOAN-KETTERING INST CAN RESEARCH
|
|
SPORE in Lymphoma
|
5P50CA126752-09
|
$2,184,999
|
$524,400
|
HESLOP, HELEN
|
BAYLOR COLLEGE OF MEDICINE
|
|
SPORE in Genitourinary Cancer
|
5P50CA091846-14
|
$1,930,400
|
$193,040
|
DINNEY, COLIN
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
|
SPORE in Cervical Cancer
|
5P50CA098252-12
|
$2,174,869
|
$282,733
|
WU, TZYY-CHOOU
|
JOHNS HOPKINS UNIVERSITY
|
|
Sleeping Beauty-Mediated microRNA Therapeutics for Metastatic Colorectal Cancer
|
5R21CA177051-02
|
$198,360
|
$99,180
|
MCIVOR, R
|
UNIVERSITY OF MINNESOTA
|
|
Role of the Perivascular Microenvironment in Primary and Metastatic Brain Tumors
|
5U54CA163167-05
|
$841,065
|
$92,517
|
HOLLAND, ERIC
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
Role of microRNAs in the regulation of CML stem cell self renewal and survival
|
5R01CA163800-04
|
$65,500
|
$19,650
|
PERROTTI, DANILO
|
UNIVERSITY OF MARYLAND BALTIMORE
|
|
Role of Dietary Zinc Transporter ZIP4 in Pancreatic Cancer
|
7R01CA138701-06
|
$289,859
|
$86,958
|
LI, MIN
|
UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR
|
|
RNA Therapeutics for Targeted Treatment of Colon Cancer
|
1R01CA186100-01A1
|
$346,325
|
$346,325
|
GUO, BIN
|
NORTH DAKOTA STATE UNIVERSITY
|
|
Reversing genetically modified T cell suppression in a model of liver metastases
|
6K08CA160662-04
|
$167,666
|
$167,666
|
KATZ, STEVEN
|
ROGER WILLIAMS MEDICAL CENTER
|
|
Research Training Program in Surgical Oncology
|
5T32CA091078-14
|
$359,864
|
$35,986
|
BLAND, KIRBY
|
UNIVERSITY OF ALABAMA AT BIRMINGHAM
|
|
Reporter Gene Technologies for Integrated Cancer Diagnostics
|
2R01CA082214-15A1
|
$375,646
|
$93,912
|
GAMBHIR, SANJIV
|
STANFORD UNIVERSITY
|
|
Regulatory T Cells and Oncolytic Virotherapy of Glioma
|
5R01CA122930-08
|
$318,015
|
$318,015
|
LESNIAK, MACIEJ
|
UNIVERSITY OF CHICAGO
|
|
Regulatory Pathways and Role of VPF/VEGF in Renal Cancer
|
2R01CA078383-16A1
|
$339,863
|
$339,863
|
MUKHOPADHYAY, DEBABRATA
|
MAYO CLINIC ROCHESTER
|
Total relevant funding to Gene Therapy for this search: $39,508,420
|